patient subgroup...
age >= 55 yr age >= 60 yr age >= 65 yr autoimmune disease corticosteroids: no corticosteroids: yes critical disease invasive ventilation no oxygen needed non invasive oxygen omicron variant BA.1 (B.1.1.529) severe disease solid organ transplant recipients subjects at risk
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
anti-inflammatoty and immuno-therapy - versus anti-inflammatoty and immuno-therapy - for COVID 19 hospitalized
method
abbreviations
Outcome
Relative effect 95%CI
LoD
Trt. better when
I2
k (RCT/OBS)
Bayesian probability
Overall ROB
Publication bias
Degree of certainty
Endpoint importance
Published MA
00 death D28 1.76 [0.58, 5.29]< 1 0% 2 studies (4/-) 15.9 % some concern not evaluable moderate crucial - deaths 0.99 [0.48, 2.05]< 1 28% 5 studies (7/-) 51.3 % some concern not evaluable moderate crucial - deaths (time to event analysis only) 3.26 [0.62, 17.12]< 1 0% 1 study (3/-) 8.2 % NA not evaluable crucial - clinical deterioration 1.28 [0.43, 3.77]< 1 0% 3 studies (3/-) 32.8 % low not evaluable high important - clinical improvement 1.34 [0.94, 1.90]> 1 36% 3 studies (3/-) 94.8 % some concern not evaluable moderate important - clinical improvement (14-day) 2.86 [1.24, 6.62]> 1 0% 1 study (1/-) 99.3 % NA not evaluable important - clinical improvement (28-day) 4.26 [1.10, 16.44]> 1 0% 1 study (1/-) 98.2 % NA not evaluable important - clinical improvement (7-day) 1.83 [0.41, 8.14]> 1 0% 1 study (1/-) 78.5 % NA not evaluable important - clinical improvement (time to event analysis only) 1.34 [0.94, 1.90]> 1 36% 3 studies (3/-) 94.8 % some concern not evaluable moderate important - death or ventilation 0.67 [0.14, 3.26]< 1 0% 1 study (1/-) 69.0 % NA not evaluable important - hospital discharge 0.88 [0.55, 1.40]> 1 0% 1 study (1/-) 28.9 % NA not evaluable important - mechanical ventilation 0.72 [0.33, 1.58]< 1 26% 4 studies (4/-) 79.2 % some concern not evaluable moderate important - radiologic improvement (14-day) 6.48 [1.72, 24.44]> 1 0% 1 study (1/-) 99.7 % NA not evaluable important - viral clearance 3.59 [1.15, 11.21]> 1 0% 2 studies (2/-) 98.6 % low not evaluable high important - viral clearance (time to event analysis only) 1.74 [1.10, 2.75]> 1 0% 1 study (1/-) 99.1 % NA not evaluable important - viral clearance by day 14 1.74 [0.71, 4.29]> 1 0% 1 study (1/-) 88.7 % NA not evaluable important - viral clearance by day 7 2.32 [1.14, 4.73]> 1 0% 2 studies (2/-) 99.0 % some concern not evaluable moderate important - 00 related SAE (TRSAE) 2.04 [0.07, 63.93]< 1 0% 1 study (1/-) 34.4 % NA not evaluable important - serious adverse events 4.54 [0.20, 105.23]< 1 0% 1 study (1/-) 17.6 % NA not evaluable important - adverse events 3.57 [0.93, 13.72]< 1 0% 1 study (1/-) 3.2 % NA not evaluable non important -
LoD: level of statistical demonstration:
